BridgeMD
A study to compare conventional "salvage" radiotherapy and individualized treatment based on results from PSMA PET/CT assessments in patients with recurrence after prostate cancer surgery
EU CTIS ID: 2023-504917-54-00
What this study is testing
To compare the efficacy of individualized PSMA PET/CT targeted treatment compared with conventional "salvage" radiotherapy in patients with biochemical recurrence after prostate cancer surgery. Main objective PSA progression free survival
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients previously treated for prostate cancer with radical prostatectomy and now having a biochemical recurrence (BCR) defined as: PSA >0.2 <2.0 ng/mL, and increasing measured twice.
- Multidisciplinary conference (MDK) decision to offer the patient salvage radiotherapy (SRT).
- Signed Informed Consent
You likely can't join if
- Previous prostate cancer with biochemical recurrence
- Previous treatment with ADT after surgery
- Previous pelvic radiotherapy
- Patients with positive lymph nodes at surgery
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.